Vivos Therapeutics
VVOS
18 hedge funds and large institutions have $3.12M invested in Vivos Therapeutics in 2023 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 14 closing their positions.
262% more capital invested
Capital invested by funds: $861K → $3.12M (+$2.26M)
167% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 3
18.73% more ownership
Funds ownership: 0.6% → 19.33% (+19%)
36% less funds holding
Funds holding: 28 → 18 (-10)
71% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$489K |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
+$430K |
| 3 |
BTI
Blue Trust Inc
Alpharetta,
Georgia
|
+$32.9K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$14.7K |
| 5 |
NFSG
Newbridge Financial Services Group
Boca Raton,
Florida
|
+$11.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$120K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$38.8K |
| 3 |
HF
HRT Financial
New York
|
-$16K |
| 4 |
Wealth Enhancement Advisory Services
Plymouth,
Minnesota
|
-$10.2K |
| 5 |
State Street
Boston,
Massachusetts
|
-$8.77K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LNC
26
Lincoln National Corp
Radnor,
Pennsylvania
| – | -$2.85K | -593 | Closed |
|
27
UBS Group
Zurich,
Switzerland
| – | -$1.78K | -370 | Closed |
|
|
CG
28
Cutler Group
San Francisco,
California
| – | -$1.99K | -232 | -95% |
|
29
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$94 | -11 | -61% |
|
30
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$38 | -8 | Closed |
|
31
JP Morgan Chase
New York
| – | -$5 | -1 | Closed |
|
VVOS Hedge Fund Activity: Q4 2023 in Review
18 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Vivos Therapeutics (VVOS) for Q4 2023, worth a combined $3.12M — up 262% from $861K a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of VVOS and 4 opened new positions — a net loss of 10 holders — while 3 trimmed existing stakes and 8 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $489K. The largest seller was Vanguard Group, cutting an estimated $120K.
- 18 institutional investors held Vivos Therapeutics (VVOS) as of Q4 2023, down from 28 in Q3 2023.
- Funds reported $3.12M of Vivos Therapeutics stock for Q4 2023, up 262% quarter-over-quarter.
- 4 funds opened new Vivos Therapeutics positions in Q4 2023 and 14 closed out, a net change of -10 holders.
- The largest Vivos Therapeutics buyer in Q4 2023 was Armistice Capital, an estimated $489K added.
- The largest Vivos Therapeutics seller in Q4 2023 was Vanguard Group, an estimated $120K sold.
Based on aggregated 13F filings for Q4 2023.